Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)

You may qualify for a clinical research study for patients with this type of melanoma. This study is being conducted to see if an investigational immunotherapy is a safe and effective therapy that can be used to reduce a person’s risk of their melanoma coming back or spreading to other areas of their body

You may be eligible for a new study if you:

  • Are male or female at least 18 years old
  • Have stage IIB or IIC melanoma
  • Are able to walk and carry out light activities

For further information, please email our Research Coordinators or call (07) 5613 2484 or go to the clinical trials section on this website